Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers

Journal of Infectious Diseases

Volumn 191, Issue 9, 2005, Pages 1515-1522

  Gordon, Bruce R ^a   Parker, Thomas S ^a   Levine, Daniel M ^a   Feuerbach, Fred ^a   Saal, Stuart D ^a   Sloan, Betty Jane ^a   Chu, Cindy ^a   Stenzel, Kurt H ^a   Parrillo, Joseph E ^b   Rubin, Albert L ^a  

^a ROGOSIN INSTITUTE   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 6; INTRALIPID; LIPID EMULSION; LIPOPROTEIN; PHOSPHOLIPID; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; ENDOTOXEMIA; ENTEROBACTER INFECTION; FEMALE; HUMAN; INFECTION PREVENTION; INFUSION; LEUKOCYTE COUNT; MALE; NEUTROPHIL; OBSERVATION; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PULSE RATE; SCORING SYSTEM; TEMPERATURE;

ADULT; EMULSIONS; ENDOTOXINS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; PHOSPHOLIPIDS; REFERENCE VALUES;

EID: 20244364838     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428908     Document Type: Article

References (33)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
2. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest 1991; 99:169-75.
3. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. CHESS Trial Study Group. Ann Intern Med 1994; 121:1-5.
4. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23:994-1006.
5. Vincent JL. New therapies in sepsis. Chest 1997; 112(Suppl 6):S330-8.
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. N Engl J Med 2001; 344:699-709.
7. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins: isolation and characterization of a bacterial lipopolysaccharide- high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67:827-37.
8. Gallay P, Heumann D, Le Roy Barras C, Glauser M. Lipopolysaccharide- binding protein as a major plasma protein responsible for endotoxic shock. Proc Natl Acad Sci USA 1993; 90:9935-8.
9. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-3.
10. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-7.
11. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, et al. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990; 58:2375-82.
12. Parker TS, Levine DM, Chang JCC, et al. Reconstituted high density lipoprotein neutralizes gram negative bacterial polysaccharides in whole human blood. Infect Immun 1995; 63:253-8.
13. Wurfel MM, Wright SD. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. J Immunol 1997; 158:3925-34.
14. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358:351-5.
15. Iribarren C, Jacobs DR Jr, Sidney S, et al. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998; 121:335-47.
16. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 1986; 32:142-5.
17. Gordon BR, Parker TS, Levine DM, et al. Low lipid levels in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 1996; 24:584-9.
18. Gordon BR, Parker TS, Levine DM, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001; 29:1563-8.
19. Levels JH, Lemaire LC, van den Ende AE, van Deventer SJ, van Lanschot JJ. Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003; 31:1647-53.
20. Chenaud C, Merlani PG, Roux-Lombard P, et al. Low apolipoprotein A-I level at ICU admission and SIRS exacerbation. Crit Care Med 2004; 32:632-7.
21. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003; 44:2339-48.
22. Levine D, Parker T, Donnelly T, et al: In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90:12040-4.
23. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993; 40:14-23.
24. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-8.
25. Goldfarb RD, Clock D, Kumar A, et al. A porcine model of peritonitis and bacteremia simulates human septic shock. Shock 1996; 6:442-51.
26. Goldfarb RD, Parker TS, Levine DM, et al. Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis. Am J Physiol Regul Integr Comp Physiol 2003; 284: 550-7.
27. Gordon BR, Parker TS, Levine DM, et al. Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion. Ann Pharmacother 2003; 37:943-50.
28. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology 1993; 187:403-16.
29. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179:1278-82.
30. Hudgins LC, Parker TS, Levine DM, et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res 2003; 44:1489-98.
31. Read TE, Grunfeld C, Kumwenda ZL, et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med 1995; 182:267-72.
32. Munford RS, Hall CL, Dietschy JM. Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins. Infect Immun 1981; 34:835-43.
33. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274:34116-22.